ER1085 (PDF)

PROGRAMA
09h30 | OPENING SESSION

13hl5 | LUNCH

Dr. Miguel Sanches

14h30 | ALK+ NSCLC: TRANSFORMING PATIENTS LIVES
09H45 | THE IMPORTANCE OF INNOVATION IN NSCLC

Chairs: Dr.3 Ana Barroso & Dr.3 Marta Soares

Chair: Jorge Correia
PhysiciarTs perspective
Prof. Dr. Antonio Araujo
Patient's perspective
Dr.3 Cristina Coelho - "Pulmonale" - Portuguese Association
for Lung Cancer

The importance of CNS preservation
in ALK+ NSCLC patients
Prof.g Dr.3 Dolores Isla

Q&A

Q&A

10h45 | DIAGNOSIS AND MOLECULAR CHARACTERIZATION
IN LUNG CANCER
Chairs: Prof. Dr. Jose Carlos Machado
& Prof. Dr. Venceslau Hespanhol
Role of molecular characterization in NSCLC management
Prof. Dr. Manuel Teixeira
The clinical benefits of Comprehensive Genomie Profiling
in lung cancer
Dr.3 Romana Wass

Q&A
11H45 | COFFEE BREAK
12H15 | LATEST DEVELOPMENTS IN THE MANAGEMENT
OF EGFR+ NSCLC

Chairs: Dr.3 Alice Pego & Dr.3 Teresa Almodóvar
Mechanism of resistance to EGFR targeted drugs
Dr.3 Paula Fidalgo
Is the treatment sequence already defined for EGFR+ patients?
Dr.g Fernanda Estevinho

Reassessing the standard of care in first linę treatment
of ALK+ NSCLC patients
Dr. Maurice Perol

15h30 | COFFEE BREAK
15h45 | IMMUNOTHERAPY: BUILDING THE FOUNDATION
FOR THE FUTURĘ
Chairs: Dr.3 Encarnaęao Teixeira
& Prof Dr. Henrique Queiroga
Immunotherapy in first-line treatment of NSCLC
Dr.3 Ana Barroso
The futurę of immunotherapy in lung cancer
Dr. Fernando Barata

Q&A
16h45 | CLOSING SESSION
17hl5 | FINAŁ REMARKS

Q&A

Roche Farmaceutica Qui'mica, Lda.
Estrada Nacional 249-1, 2720-413 Amadora
Tel.: +351 214 257 000 | Fax: +351 214 186 677 | www.roche.pt
Cont. n° 500 233 810
PT/LUN/0118/0001a, Jan 2018